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BRIEF DEFINITIVE REPORT
Lineage commitment is a recurring theme 
throughout hematopoiesis, the process by 
which hematopoietic stem cells (HSCs) give 
rise to all classes of blood cells (1, 2). Multiple 
developmental intermediates downstream of 
HSCs have been prospectively isolated and 
characterized in the bone marrow, which en-
able us to gain insights into the sequential mo-
lecular events that occur during the process of 
maturation to diff  erent hematopoietic lineages 
(3, 4). Nonetheless, when and how the fi  rst 
step of lineage restriction occurs from HSCs 
remains obscure (5).
Early in their diff  erentiation,  long-term 
(LT)-HSCs lose their capacity for self-renewal, 
diff  erentiating fi  rst into short-term (ST)-HSCs 
and subsequently to multipotent progenitors 
(MPPs). MPPs have very limited or no self-
renewal activity but retain the potential for 
multilineage diff  erentiation (6, 7). It was postu-
lated that the fi   rst step of lineage restriction 
  occurs at this developmental stage, where MPPs 
are specifi  ed to either the lymphoid or myeloid 
lineage, the two major branches of hemato-
poietic cells (8). Identifi  cation of common 
lymphoid progenitors (CLPs) and common 
myeloid progenitors (CMPs), which diff  er-
entiate exclusively to specifi  c cell lineages, 
  supported this model of MPP diff  erentiation 
(9, 10). Although lineage specifi  cation is widely 
thought to occur at the MPP stage (1), no clear 
evidence established the developmental hierar-
chy of MPPs and lineage-restricted   progenitors. 
Recently, we demonstrated the ability of a 
subset of MPPs in giving rise to CMPs in vivo. 
In this previous study, we showed that the 
MPP population, defi  ned as the Flt3+Thy-1.1− 
cells in the c-KithiLin−Sca-1hi (KLS) fraction 
of bone marrow, can be subdivided into two 
subpopulations based on vascular cell adhe-
sion mol  ecule 1 (VCAM-1) expression (11). 
Although VCAM-1− MPPs possess robust clonal 
granulocyte/macrophage (GM) and lymphoid 
diff  erentiation potential in vitro, VCAM-1− 
MPPs preferentially become lymphocytes in vivo.
VCAM-1+ MPPs can give rise to CMPs and 
VCAM-1− MPPs, suggesting that VCAM-1+ 
MPPs represent a branching point between the 
lymphoid and myeloid lineages (11). Interest-
ingly, Adolfsson et al. (12) demonstrated that 
Flt3+KLS cells lack   erythroid diff  erentiation 
potential, but have potent   lympho-myeloid 
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diff  erentiation potential in vitro. Their result challenged the 
hierarchy of MPPs and CMPs during diff  erentiation  and 
raised the possibility that the erythroid lineage diverges ear-
lier than the GM lineage, or that there are multiple branching 
points for myeloid diff   erentiation during hematopoiesis. 
However, the report by Adolfsson et al. (12) is inconsistent 
with our fi  ndings (11) and an earlier study by Christensen 
et al. (7), showing that Flt3+KLS cells are either ST-HSCs or 
MPPs. These discrepancies prompted us to reevaluate the 
diff  erentiation potential of VCAM-1+ MPPs more carefully.
In this study, we found that all VCAM-1− MPPs homo-
geneously express high levels of Flt3, whereas VCAM-1+ 
MPPs can be subdivided into Flt3lo and Flt3hi populations. 
  Flt3loVCAM-1+ MPPs have erythroid diff  erentiation potential 
and can produce CMPs. In contrast, Flt3hiVCAM-1+ MPPs 
lack robust erythroid diff   erentiation potential but retain a 
GM diff  erentiation potential that is similar to Flt3loVCAM-1+ 
MPPs in vivo. Flt3hiVCAM-1− MPPs, conversely, give rise 
to erythroid and GM lineages at basal levels only and prefer-
entially develop into lymphocytes in vivo. The inability of 
Flt3hi VCAM-1+ MPPs to give rise to CMPs implicates an 
alternative pathway for GM lineage diff  erentiation indepen-
dent of CMPs in vivo. Our results suggest that the divergence 
of the lymphoid and myeloid lineages during early hemato-
poiesis occurs asymmetrically at distinct progenitor stages.
RESULTS AND DISCUSSION
Purifi  cation of Flt3lo and Flt3hi MPPs
It has been shown that HSCs and MPPs can be separated in 
the KLS bone marrow fraction using the Thy-1.1 and Flt3 
markers (7). LT-HSCs are highly enriched in the CD34−/lo 
fraction of the Thy-1.1loFlt3− KLS population (13, 14), 
whereas CD34+ Thy-1.1loFlt3− KLS and Thy-1.1loFlt3+ 
KLS cells represent ST-HSCs (7, 14). MPPs comprise the 
Thy-1.1−Flt3+ KLS cell population (7, 11). Although all 
HSCs are VCAM-1+, the MPPs can be subdivided into three 
distinct populations based on Flt3 and VCAM-1 expression 
(Fig. 1 A). VCAM-1− MPPs uniformly express high levels of 
Flt3, whereas the VCAM-1+ MPP population contains both 
Flt3lo and Flt3hi subsets. After two rounds of FACS sorting, 
we could isolate these MPP subsets to >95% purity (Fig. 1 B). 
c-Kit and Sca-1 expression levels were comparable among 
the three MPP subsets (Fig. S1 A, available at http://www.
jem.org/cgi/content/full/jem.20060697/DC1). In addition, 
Flt3 expression by ST-HSC was similar to that of Flt3lo-
VCAM-1+ MPPs, whereas LT-HSCs were Flt3− on FACS 
analyses (Fig. S1 B). We compared the diff  erentiation poten-
tials of these three purifi   ed subsets of MPPs to diff  erent 
  hematopoietic lineages.
Erythroid differentiation potential is enriched 
in Flt3loVCAM-1+ MPPs
We fi   rst evaluated the in vitro megakaryocyte/erythroid 
(MegE) diff  erentiation potential of MPP subsets by compar-
ing their colony-forming activities. MPPs were cultured in 
methylcellulose in the presence of stem cell factor, IL-3, 
IL-6, erythropoietin (Epo), and thrombopoietin. In these 
cultures, only Flt3loVCAM-1+ MPPs produced obvious 
  erythroid (CFU-E) or mixed (CFU-GEMM) colonies, at 4.3 
and 8.7%, respectively (Fig. 2 A). Neither Flt3hiVCAM-1+ 
MPPs nor Flt3hiVCAM-1− MPPs exhibited the capacity to 
generate erythroid or mixed colonies (<1%; Fig. 2 A). In 
  addition, Flt3loVCAM-1+ MPPs, but not Flt3hiVCAM-1+ 
MPPs or Flt3hiVCAM-1− MPPs, expressed signifi  cant levels 
of GATA1 and EpoR (Fig. 2 B), suggesting that erythroid 
colony potential and expressions of erythroid lineage–affi   li-
ated genes are correlated.
To examine the MegE diff  erentiation potential of MPP 
subsets in vivo, we purifi  ed each MPP type from enhanced 
GFP (EGFP) mice and injected it into lethally irradiated 
Figure 1.  Subfractionation of MPPs by Flt3 and VCAM-1 expression. 
(A) Flt3 and VCAM-1 expression on HSCs and MPPs by FACS analysis. 
(B) FACS analysis of Flt3 and VCAM-1 expression levels on MPP subsets 
after two rounds of sorting. The purity of the sorted populations 
was >95%.BRIEF DEFINITIVE REPORT
hosts as described by NaNakorn et al. (15). In this assay 
system, MegE diff  erentiation potential is evaluated based on 
the donor chimerism (GFP+) of platelets in peripheral blood 
(Fig. 2 C). 2 wk after transfer, Flt3loVCAM-1+ MPPs con-
tributed to 16–20% platelet chimerism. In contrast, trans-
fer of Flt3hiVCAM-1+ or Flt3hiVCAM-1− MPPs resulted 
in platelet chimerism of only 3.4 and 1.5%, respectively 
(Fig. 2 D). In the report by Adolfsson et al. (12), lymphoid-
primed MPPs (LMPPs; Flt3+KLS) lacking erythroid diff  er-
entiation potential were characterized in the 25% highest 
Flt3-expressing cells of the KLS fraction. Our result is 
consistent with their fi  ndings that Flt3hiKLS cells do not 
contribute signifi  cantly to erythroid diff  erentiation. None-
theless, we did observe low numbers of platelets derived 
from Flt3hiVCAM-1+ and Flt3hiVCAM-1− MPPs (Fig. 
2 D), perhaps due to the high sensitivity of our detection 
system or to the early determination of platelet chimerism. 
As MPPs have a limited self-renewal activity and can only 
reconstitute the hematopoietic system transiently (7), low 
frequencies of MegE lineage cells might not be present at 
later time points.
MPP subsets show different potentials for GM 
differentiation in vivo and defi  ne a developmental hierarchy
Although their potential for MegE diff  erentiation was dra-
matically reduced, the GM potential of Flt3hiVCAM-1+ 
MPPs was equivalent to Flt3loVCAM-1+ MPPs, as deter-
mined by chimerism at 2 wk after transfer (16 and 22%, re-
spectively; Fig. 2 D). In contrast, Flt3hiVCAM-1− MPPs had 
little capacity for GM diff  erentiation (4% chimerism; Fig. 
2 D), as we demonstrated previously (11). All three MPP 
subsets could give rise to T and B cells in vivo, although 
the kinetics of lymphocyte production by Flt3loVCAM-1+ 
MPPs was delayed in comparison to Flt3hiVCAM-1+ MPPs 
and Flt3hiVCAM-1− MPPs (Fig. 3 A). This delay suggests 
that Flt3loVCAM-1+ MPPs are less mature than either 
Flt3hiVCAM-1+ or Flt3hiVCAM-1− MPPs. Given our pre-
vious demonstration that VCAM-1+ MPPs can give rise 
to VCAM-1− MPPs (11), it is reasonable to conclude that 
Flt3hiVCAM-1+ MPPs are more immature than Flt3hiVCAM-1− 
MPPs. We did not, however, observe any diff  erence  in 
B cell diff   erentiation kinetics after reconstitution with 
Flt3hiVCAM-1+ or Flt3hiVCAM-1− MPPs, perhaps because 
the transition between the two populations is rapid or be-
cause of the higher proliferative capacity of Flt3hiVCAM-1+ 
MPPs. Collectively, our results suggest a developmental 
  hierarchy among MPP subsets, with Flt3loVCAM-1+ MPPs 
being the most primitive with full multilineage diff  erentia-
tion potential. The more mature Flt3hiVCAM-1+ MPPs lose 
the capacity for erythroid diff  erentiation and in turn, diff  er-
entiate into Flt3hiVCAM-1− MPPs that preferentially gener-
ate lymphocytes in vivo.
Lymphoid lineage priming in Flt3hiVCAM-1−, 
but not Flt3hiVCAM-1+, MPPs
Lineage priming, the promiscuous expression of lineage-
  affi   liated genes, is thought to be important in the develop-
mental plasticity of progenitor cells with the potential to 
produce multiple lineages (16–19). Yet despite their de-
velopmental potential for the lymphoid lineages,   several 
Figure 2.  MegE differentiation potential is restricted to Flt3lo-
VCAM-1+ MPPs. (A) In vitro MegE and GM differentiation potential 
of MPP subsets assessed by colony-forming assay on methylcellulose. 
Data represent the average plating effi  ciency of triplicate methylcellulose 
  cultures of each MPP population. (B) Comparison of MegE-affi  liated 
GATA1 and EpoR expression levels in HSCs, MPP subsets, CLPs, and MEPs 
by   quantitative PCR analysis. GATA1 and EpoR expression levels in HSCs 
were arbitrarily defi  ned as unit 1. Data shown represent the mean value 
from triplicate reactions. (C) In vivo MegE differentiation by Flt3loVCAM-1+ 
MPPs. Peripheral blood from recipient mice injected with Flt3loVCAM-1+ 
MPPs was analyzed at 2 wk after injection to detect donor-derived 
(GFP+) CD41+CD61+ platelets. (D) Comparison of in vivo MegE and GM 
differentiation potential of MPP subsets. Peripheral blood from recipient 
mice injected with purifi  ed MPP subsets was analyzed at 2 wk after injec-
tion to evaluate the donor chimerism (GFP+) of CD41+CD61+ platelets 
(○) or Mac-1+ GM cells (●). Horizontal bars in the graph denote the 
average values from three mice analyzed in each group. *, P < 0.05, cal-
culated by the Student’s t test compared with percentage of chimerism of 
Flt3loVCAM-1+ MPPs.
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observed in HSCs (20, 21). As some lymphoid-related genes 
are expressed in MPPs, the lymphoid lineage diff  erentia-
tion program might be activated in the MPP stage before 
commitment to the lymphoid lineages (18, 22). RAG1 and 
IL-7Rα are among the earliest lymphoid-related genes ex-
pressed in MPPs (11, 12, 22); therefore, we examined the 
RAG1 and IL-7Rα expression in HSCs and the MPP sub-
sets. RAG1 and IL-7Rα transcripts were virtually absent 
in HSCs, Flt3loVCAM-1+, and Flt3hiVCAM-1+ MPPs, but 
were up-regulated in Flt3hiVCAM-1− MPPs (Fig. 3 B). 
We also found that a signifi  cant proportion (30–50%) of 
VCAM-1− MPPs expressed RAG1 by monitoring GFP 
expression in RAG1-GFP knock-in mice, whereas only 
a small fraction (<5%) of VCAM-1+ MPPs are GFP+ 
(  unpublished data). These observations confi  rm our earlier 
fi  nding that although some VCAM-1− MPPs are IL-7Rα+, 
all VCAM-1+ MPPs are IL-7Rα− (11). These data also sug-
gest that initiation of lymphoid lineage priming and loss of 
erythroid diff  erentiation potential do not occur simultane-
ously in MPPs. Upon loss of MegE diff  erentiation ability, 
Flt3hiVCAM-1+ MPPs retain robust GM diff  erentiation po-
tential in vivo without lymphoid lineage priming. Subsequent 
activation of lymphoid-related gene expression in more ma-
ture Flt3hiVCAM-1− MPPs potentiates their development 
into lymphocytes in vivo.
Flt3loVCAM-1+ MPPs can give rise to CMPs
We previously demonstrated that VCAM-1+ MPPs can 
give rise to CMPs (11). Consequently, to clarify their 
  developmental relationship, we evaluated the ability of 
Flt3loVCAM-1+ and Flt3hiVCAM-1+ MPPs to differenti-
ate into CMPs. 6 d after the transfer of purified MPP 
populations, phenotypic CMPs were detected only in 
hosts given Flt3loVCAM-1+ MPPs (Fig. 4 A). As we dem-
onstrated   previously, CMPs derived from VCAM-1+ 
MPPs are   functionally comparable to freshly isolated 
CMPs and have complete erythroid and GM differentia-
tion potential (11). The high in vivo GM contribution 
but the lack of CMP (and GM progenitor [GMP]) differ-
entiation from Flt3hiVCAM-1+ MPPs suggests that there 
may be an alternative GM differentiation pathway inde-
pendent of CMPs or even GMPs. Because CMP could 
only be generated from Flt3loVCAM-1+ MPPs, we rede-
fi  ne the MPP→CMP branching point to the Flt3loVCAM-1+ 
MPP compartment. In addition, an alternative GM dif-
ferentiation pathway branches from Flt3hiVCAM-1+ 
MPPs (Fig. 4 B).
Figure 3.  Lymphoid lineage differentiation potential and lymphoid 
lineage priming in MPP subsets. (A) All MPP subsets contributed to lym-
phoid lineage differentiation in vivo. Peripheral blood collected from recon-
stituted mice was analyzed for donor-derived B220+ B cells and CD3+ T cells 
at 3–5 wk after injection. FACS plot shown is pregated on GFP+CD45.1− 
population. Almost all B220+ cells are CD19+IgM+, and most CD3+ cells 
are TCRβ+ in the peripheral blood (Fig. S2). It should be noted that due 
to the setting of the FACS machine, the CD3+ population does not 
clearly appear in the plots. (B) Analysis of lymphoid-specifi  c RAG1 and
 IL-7Rα expression levels in MPP subsets by quantitative PCR. Data shown 
represent the mean value from triplicate reactions. RAG1 and IL-7Rα ex-
pression levels in CLPs were arbitrarily set at 10,000 and 100, respectively.
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Our detailed study of MPPs reveals that the initial step of 
lineage restriction during hematopoiesis is not simply lym-
phoid versus myeloid commitment. Instead, the fi  rst step in 
lineage restriction occurs in Flt3loVCAM-1+ MPPs, which 
are fully multipotent but possess limited or no self-renewal 
activity. We conclude that the earliest restriction in hemato-
poietic potential coincides with the loss of self-renewal ability 
in HSCs. Based on the results in our present and previous 
studies (11), we propose that there is a hierarchy in MegE, 
GM, and lymphoid diff  erentiation during adult hematopoie-
sis (Fig. 4 B). In the course of early lymphoid diff  erentiation, 
hematopoietic progenitors sequentially and gradually lose 
MegE and GM diff  erentiation potential before lymphoid lin-
eage commitment. The developmental hierarchy of the MPP 
subsets, based on their in vivo diff  erentiation potential to ery-
throid, myeloid, and lymphoid lineages, supports the sequen-
tial diff  erentiation model proposed by Brown et al. (23).
The LMPPs defi  ned by Adolfsson et al. (12) express IL-
7Rα and are most comparable to Flt3hiVCAM-1− MPPs 
characterized in our previous and current report (Fig. 3 B) 
(11). From the view of their physiological contribution in 
vivo, but not their diff  erentiation potential in vitro, it may 
be most appropriate to consider Flt3hiVCAM-1+ MPPs as 
bipotent progenitors for lymphoid and GM populations, 
even though lymphoid priming is not observed in these cells. 
Activation of lymphoid-related genes in the later LMPP or 
Flt3hiVCAM-1− MPPs directs them toward the lymphoid 
lineage, even though they can diff  erentiate into GM cells 
in vitro with the appropriate cytokine signals (11). Because 
of limitation of the in vitro culture system, it is diffi   cult to 
determine the proportion of clonal Flt3hiVCAM-1− MPPs 
with potentials for all three T, B, and GM lineages. It is pos-
sible that this MPP subset is heterogeneous, which may be 
composed of progenitors with various potentials, such as 
T/B/GM, T/B, T/GM, etc. Indeed, Flt3hiVCAM-1− MPPs are 
heterogeneous for gene expressions, such as IL-7Rα (11) and 
RAG1 (ELP-like cells in RAG1/GFP KI mice; unpublished 
data). Perhaps the promiscuous expression of both lymphoid 
and myeloid lineage genes in the LMPP or Flt3hiVCAM-1− 
MPPs, followed by the silencing of myeloid-affi   liated genes, 
serves as a prerequisite to lymphoid lineage commitment 
(unpublished data). Ana  lysis of MPP subsets at the molecu-
lar level should facilitate the investigation of how stochas-
tic events at the molecular level and infl  uence by extrinsic 
Figure 4.  Flt3loVCAM-1+ MPPs, but not Flt3hiVCAM-1+ MPPs, 
differentiate into CMPs in vivo. (A) Detection of CMPs, GMPs, and 
MEPs derived from Flt3loVCAM-1+ MPPs and Flt3hiVCAM-1+ MPPs. Equal 
number of cells from the two MPP populations (CD45.2) were injected 
into CD45.1+ recipient mice. Bone marrow cells were harvested 6 d after 
injection for FACS analysis, and the total cell number of donor-derived 
CMPs, GMPs, and MEPs in recipient mice from two independent experi-
ments is shown. FACS plots of these donor-derived bone marrow popula-
tions are shown in Fig. S3. Although the chimerism of donor-derived cells 
in the bone marrow varied between experiments, the difference in the 
contribution of CMPs, GMPs, and MEPs from Flt3loVCAM-1+ MPPs and 
Flt3hiVCAM-1+ MPPs remained consistent. (B) Proposed model of hierar-
chy in MPP subsets and lymphoid- and myeloid lineage–restricted pro-
genitors during hematopoiesis, based on in vivo differentiation potential 
of MPPs. Flt3loVCAM-1+ MPPs represent the fi  rst branching point during 
adult hematopoiesis, which diverge into CMPs and Flt3hiVCAM-1+ MPPs. 
Flt3hiVCAM-1+ MPPs represent the second branching point, diverging to 
lymphoid lineage and a GM differentiation pathway that is independent 
of CMPs. Because Flt3hiVCAM-1− MPPs do not contribute to GM lineages 
signifi  cantly in vivo, we consider these MPPs as lymphoid-specifi  ed pro-
genitors before lymphoid lineage commitment in CLPs or pro–T cells in 
the thymus. Dotted lines represent potential migration of bone marrow 
progenitor candidates to the thymus for T cell development based on 
evidence by recent studies (reference 25).1872   SEQUENTIAL LOSS OF MYELOID POTENTIAL IN HEMATOPOIESIS | Lai and Kondo
factors are coordinated to determine lineage choice at these 
early branch points of hematopoiesis.
MATERIALS AND METHODS
Mice. Wild-type mice used in this study were C57BL/Ka-Thy-1.1 and 
C57BL/Ka-Thy-1.1-Ly5.2 (CD45.1). EGFP mice were generated as de-
scribed previously (24) and backcrossed onto the C57BL/Ka-Thy-1.1 back-
ground for more than eight generations. For characterization and purifi  cation 
of bone marrow populations, 6–8-wk-old mice were used. Recipient mice 
used for reconstitution studies were 8–12 wk of age. All mice were main-
tained under specifi   c pathogen-free conditions at the Duke University 
  Animal Care Facility. All studies and procedures were approved by the Duke 
University Animal Care and Use Committee.
Flow cytometry. Antibodies used in this study are listed in supplemental 
Materials and methods, available at http://www.jem.org/cgi/content/full/
jem.20060697/DC1. Preparation of single cell suspension, magnetic beads 
separation, and antibody staining of cells were performed as described previ-
ously (11). Cell sorting and cell surface phenotyping were performed on a 
FACSVantage SE with a DiVa option (488 nm argon, 599 nm dye, and 408 nm 
krypton lasers; BD Bioscience Flow Cytometry Systems), which is avail-
able in the FACS facility of Duke Comprehensive Cancer Center. To adjust 
the compensation of signals from diff  erent fl  uorescent channels, we per-
formed single-color staining on splenocytes with anti-B220 antibodies con-
jugated to each fl  uorochrome. The stained splenocyte samples were analyzed 
on FACSVantage, and the DiVa software computationally determined com-
pensation values. Data were analyzed with FlowJo software (Treestar). Dead 
cells were gated out from analyses and cell sortings as propidium iodide–
  positive cells.
Analysis of in vitro and in vivo lineage diff  erentiation potentials. 
In vitro methylcellulose colony assays were performed as described   previously 
(11). For analysis of in vivo diff  erentiation potential to various hematopoietic 
lineages, 103 Flt3loVCAM-1+, Flt3hiVCAM-1+, or Flt3hiVCAM-1− MPPs 
(EGFP+CD45.2+) were injected into lethal dose (950 rad) –irradiated hosts 
(CD45.1) with 2 × 105 whole bone marrow cells (CD45.1) for radioprotec-
tion. Peripheral blood was obtained at various time points from reconstituted 
mice for FACS analysis as described above. For analysis of CMP, GMP, and 
megakaryocyte-erythroid progenitor (MEP) diff  erentiation from MPP sub-
sets, 2.5 × 104 Flt3loVCAM-1+ or Flt3hiVCAM-1+ MPPs (CD45.2) were 
injected into lethally irradiated host (CD45.1). Bone marrow cells were har-
vested from femurs and tibiae 6 d after injection and subjected to FACS 
analysis as described above.
Quantitative PCR analysis. Cells were deposited directly into 1.5-ml mi-
crocentrifuge tubes with 1 ml TRIzol reagent (Invitrogen) during the sec-
ond round of sorting. Total RNA was isolated according to the manufacturer’s 
instructions. After treatment with DNase I (Invitrogen), fi  rst-strand cDNA 
synthesis was performed using Superscript III reverse transcriptase and oligo-
dT primers (Invitrogen). Gene expression levels were quantifi  ed using the 
iCycler real-time PCR detection system (Bio-Rad Laboratories) and calcu-
lated and normalized to GAPDH expression level using the Relative Expres-
sion Software Tool provided by M. Pfaffl    (Technical University of Munich, 
Munich, Germany). The PCR primers used are listed in supplemental 
  Materials and methods.
Online supplemental material. Fig. S1 compares the surface expressions 
of c-Kit, Sca-1, and Flt3 on MPP subsets. Fig. S2 shows further characteriza-
tion of B220+ and CD3+ cells in the peripheral blood, demonstrating that 
the majority of them are B and T cells, respectively. Fig. S3 shows the FACS 
plots of myeloid progenitors derived from Flt3loVCAM-1+ and Flt3hiVCAM-1+ 
MPPs in vivo. Supplemental Materials and methods lists all the antibodies, 
defi  nitions of bone marrow populations, and PCR primers used in this 
study. The online supplemental material is available at http://www.jem.
org/cgi/content/full/jem.20060697/DC1.
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